Refine by
Intellia Protein Expression Equipment & Supplies
1 equipment items found
by:Intellia Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
Our first ex vivo development candidate seeks to treat acute myeloid leukemia (AML) by engineering autologous T cell receptors (TCR) directed towards the Wilms’ Tumor 1 (WT1) antigen, an over-expressed protein that is often associated with AML and other cancers. We have nominated NTLA-5001 as our initial development candidate for AML and expect to enter the ...